<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:fa8f4713-044c-413a-8d5f-d37d2e849a22,g:e5c36a90-a065-41b9-aa68-f4789c60c9f7,d:2ce49310ee594112839ea47f820e2632--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20210827</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl80L2ZyYWc6N2UzMGNmNTFmNjUyNDMwNGFhMTRiNGYwYTk0M2I3ZDMvdGFibGU6YjBmMjZlMmJmZWE3NGVlNmIwMzA0ZmFiNjIyNjNkZGEvdGFibGVyYW5nZTpiMGYyNmUyYmZlYTc0ZWU2YjAzMDRmYWI2MjI2M2RkYV8yLTEtMS0xLTA_4eea01a7-cfbc-432c-ace2-f43a334c62c9">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl80L2ZyYWc6N2UzMGNmNTFmNjUyNDMwNGFhMTRiNGYwYTk0M2I3ZDMvdGFibGU6YjBmMjZlMmJmZWE3NGVlNmIwMzA0ZmFiNjIyNjNkZGEvdGFibGVyYW5nZTpiMGYyNmUyYmZlYTc0ZWU2YjAzMDRmYWI2MjI2M2RkYV81LTEtMS0xLTA_69e03358-7b26-4acc-beb3-408d49c4d472">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20210827.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i042719179fe74eb688302f453d23fde9_D20210827-20210827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-27</xbrli:startDate><xbrli:endDate>2021-08-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2ce49310ee594112839ea47f820e2632_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTc0_423a08c0-bae2-49e2-aea1-4dbe518b5117">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNzc_af9ad078-4c80-4843-a910-7e51ec0ef044">August 27, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:21.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTgx_c019faa0-2945-4852-afba-a4e7ee55a547">ANGION BIOMEDICA CORP.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8wLTAtMS0xLTA_5ea51739-084d-4a16-b833-9b22343ae95c">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8wLTEtMS0xLTA_025b6ab5-a8dc-41cb-b9be-bc7d0962e99d">001-39990</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8wLTMtMS0xLTA_c5271551-e766-4e69-aeba-454d17c7f4aa">11-3430072</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8zLTAtMS0xLTA_47bd886e-418a-4427-8f20-c153c7626c98">51 Charles Lindbergh Boulevard</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8zLTEtMS0xLTA_0bca8c23-a86f-4273-8312-124ffe3ae59c">Uniondale</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8zLTItMS0xLTA_f45213c8-ae5f-4beb-a6d0-0e4c21f4c7b2">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YmY3NGM5ZTk1ZDg0NDY0YjljMDUxZWY5ZGMzMWQyOTQvdGFibGVyYW5nZTpiZjc0YzllOTVkODQ0NjRiOWMwNTFlZjlkYzMxZDI5NF8zLTMtMS0xLTA_c8d2bfd0-b66a-401a-8484-fbf0cccba28e">11553</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTgy_0476a195-ab29-44f9-bc3d-e88222b93c7d">415</ix:nonNumeric>) <ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTgz_001b76db-51fc-461a-a23c-d531ba154c36">655-4899</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTc1_ac3293dd-3126-4ed1-80c5-b1d8fe760af3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTc3_a061b000-45ad-4466-98a2-0bb10fc77726">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTc2_2396c075-1ba5-452d-ac17-1993a05a2858">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTc4_3cc30a74-2ef3-404f-869a-1ebfbecf64b4">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YTE0MWE1NTE5MjI2NGZhMWJlZmE4NTQzNTg0ZGYxZWMvdGFibGVyYW5nZTphMTQxYTU1MTkyMjY0ZmExYmVmYTg1NDM1ODRkZjFlY18xLTAtMS0xLTA_169ce783-c94e-4957-894f-a7c43edb1da5">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YTE0MWE1NTE5MjI2NGZhMWJlZmE4NTQzNTg0ZGYxZWMvdGFibGVyYW5nZTphMTQxYTU1MTkyMjY0ZmExYmVmYTg1NDM1ODRkZjFlY18xLTEtMS0xLTA_5e548e79-a9bd-423d-bc8a-10803c4a59b3">ANGN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGFibGU6YTE0MWE1NTE5MjI2NGZhMWJlZmE4NTQzNTg0ZGYxZWMvdGFibGVyYW5nZTphMTQxYTU1MTkyMjY0ZmExYmVmYTg1NDM1ODRkZjFlY18xLTItMS0xLTA_d9e14a48-fe3a-4c46-b50c-add8b4fbeb2c">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xMzEx_c62f3e90-1cd6-4e3e-82e6-8cc8f874eb00">&#9746;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042719179fe74eb688302f453d23fde9_D20210827-20210827" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjJjZTQ5MzEwZWU1OTQxMTI4MzllYTQ3ZjgyMGUyNjMyL3NlYzoyY2U0OTMxMGVlNTk0MTEyODM5ZWE0N2Y4MjBlMjYzMl8xL2ZyYWc6MTEzZTg5ZWQ5NTU5NDU3ODhlNTc0NjQ2MTU1OGM4YTYvdGV4dHJlZ2lvbjoxMTNlODllZDk1NTk0NTc4OGU1NzQ2NDYxNTU4YzhhNl8xNTcz_39c15a6a-d883-44a9-b441-5a4639b87a91">o</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ce49310ee594112839ea47f820e2632_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.02 Termination of Material Definitive Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 27, 2021, Angion Biomedica Corp. (&#8220;Angion&#8221;) received written notice from Sinovant Sciences HK Limited (&#8220;Sinovant&#8221;) that on November 25, 2021 Sinovant intends to terminate its exclusive license agreement with Angion dated August 22, 2018 (the &#8220;Agreement&#8221;), pursuant to which Sinovant is responsible for the clinical development and, if approved, commercialization of ANG-3777 for all indications within Greater China.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Specifically, Sinovant informed Angion that its decision to terminate the Agreement is in no way related to the clinical development or economic potential for ANG-3777 in Greater China but is entirely due to a change in Sinovant&#8217;s strategic direction.  Based upon the terms of the Agreement, Sinovant must provide Angion ninety days written notice to Angion prior to termination.  There are no fees, payments, or other financial remuneration due to either Angion or Sinovant resulting from the termination of the Agreement.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Angion is evaluating its strategic options to maximize the value of the clinical development and commercialization rights for ANG-3777 in Greater China, including engaging in ongoing discussions with potential partners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ce49310ee594112839ea47f820e2632_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Jennifer J. Rhodes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: August 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jennifer J. Rhodes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "angn-20210827.htm", "description": "8-K", "secsgml_size_bytes": 32906}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39990", "film-number": "211220899"}, "business-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553", "phone": "(415) 655-4899"}, "mail-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553"}}
angn-20210827
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
August 27, 2021
Date of Report (date of earliest event reported)
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
51 Charles Lindbergh Boulevard
Uniondale
New York
11553
(Address of Principal Executive Offices)
(Zip Code)
(
415
)
655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ANGN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 1.02 Termination of Material Definitive Agreement
On August 27, 2021, Angion Biomedica Corp. ("Angion") received written notice from Sinovant Sciences HK Limited ("Sinovant") that on November 25, 2021 Sinovant intends to terminate its exclusive license agreement with Angion dated August 22, 2018 (the "Agreement"), pursuant to which Sinovant is responsible for the clinical development and, if approved, commercialization of ANG-3777 for all indications within Greater China.
Specifically, Sinovant informed Angion that its decision to terminate the Agreement is in no way related to the clinical development or economic potential for ANG-3777 in Greater China but is entirely due to a change in Sinovant's strategic direction.  Based upon the terms of the Agreement, Sinovant must provide Angion ninety days written notice to Angion prior to termination.  There are no fees, payments, or other financial remuneration due to either Angion or Sinovant resulting from the termination of the Agreement.
Angion is evaluating its strategic options to maximize the value of the clinical development and commercialization rights for ANG-3777 in Greater China, including engaging in ongoing discussions with potential partners.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANGION BIOMEDICA CORP.
By:
/s/ Jennifer J. Rhodes
Date: August 30, 2021
Jennifer J. Rhodes
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary